Study funded by Susan G. Komen shows promise at Vandy
By Kim Swindell Wood | March 9, 2018 3:33 pm
Komen Central Tennessee Survivor Volunteers, Grantees and Komen Leadership toured the breast cancer lab in the Vanderbilt Ingram Cancer and Research Center.
Sixteen participants from Nashville, Chattanooga and Cookeville areas were shown the process of a potentially life saving drug from lab to market. Dr. Deborah Lannigan-Macara and her team of researchers are working with a South American plant derivative that has shown positive results at killing cancer cells. The group saw the studies on treating breast cancer cells with this drug compared to a control of no drug treatment or a current FDA approved drug. The study is on it’s fifth year of a 15 year projected research timeline.
The researchers are also studying new treatment methods that could result in testing drugs on patient tissues before they are prescribed a treatment regime. This would give the patient the drug regime that worked best on their own breast cancer tissues tested in the lab.
Dr. Lannigan-Macara’s research is funded by Susan G. Komen’s national research grants. Komen is the largest nonprofit funder of breast cancer research (outside of the U.S. government). Tennessee is fortunate that Komen donations and money raised in the Central TN region fund research in this Vanderbilt study.
Komen has a bold goal of reducing breast cancer deaths in the U.S. by 50 percent by 2026. These breast cancer researchers are focused on finding the cure and more effective ways to treat breast cancer patients.